Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
Zacks
More News
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
Zacks
Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
Zacks
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
Zacks
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
Zacks
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.
Zacks
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio...
Nasdaq News: Markets
Can BMY's First CELMoD Approval Support Its Growth Strategy?
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.